Artem Smirnov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Artem Smirnov has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Eleonora Candi
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
28 shared publications - Gerry Melino
Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, Rome, Italy
21 shared publications Gerry Melino
Dept. of Experimental Medicine, University of Rome Tor Vergata, TOR, Rome, Italy
10 shared publications- Alessandro Mauriello
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
7 shared publications - Anna Maria Lena
Department of Experimental Medicine, University of Rome “Tor Vergata
7 shared publications Alessandro Mauriello
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
6 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2674
Clinical and Molecular Characterization of a Family with Punctate Palmoplantar Keratoderma Type 1 (AAGAB-pEDD) Carrying a Previously Unreported AAGAB Nonsense Variant
Background: Punctate palmoplantar keratoderma type 1 (PPPK1) is a rare inherited disorder characterized by hyperkeratotic papules affecting the palms and soles. AAGAB-related PPPK1 has recently been designated AAGAB-pEDD within a proposed gene-based classification of palmoplantar epidermal differentiation disorders. Here, we describe a multi-generational family in which we identified a previously unreported heterozygous nonsense variant in AAGAB, NM_024666.5:c.739C>T (p.Gln247Ter). The variant was identified in the proband and her affected father, as well as in her 15-year-old daughter, who is currently unaffected. This familial distribution is compatible with the autosomal dominant inheritance and age-dependent penetrance described for PPPK1. Methods: Clinical and histopathological evaluations were performed in the affected family members, followed by molecular genetic analysis to identify the underlying AAGAB variant. Variant interpretation was conducted according to established criteria. Immunofluorescence analysis of lesional skin was performed to investigate AAGAB expression and distribution. In addition, calcium-induced differentiation of Ker-CT keratinocytes was used to assess changes in AAGAB expression alongside the differentiation markers K14 and K10. Results: The previously unreported heterozygous nonsense variant in AAGAB, p.Gln247Ter variant, introduces a premature termination codon, and it is predicted to result in AAGAB loss of function through nonsense-mediated mRNA decay and/or production of a truncated protein lacking the C-terminal region if the mutant transcript were to escape NMD, contributing to AAGAB dimerization and interactions with the AP1 and AP2 adaptor complexes. Immunofluorescence analysis of lesional skin showed an altered pattern of AAGAB immunoreactivity in suprabasal keratinocytes. During calcium-induced differentiation of Ker-CT keratinocytes, representative immunofluorescence images showed an apparent reduction in AAGAB staining, accompanied by decreased K14 and increased K10 expression. Conclusions: These findings expand the mutational spectrum of AAGAB-related PPPK1 and provide additional evidence that AAGAB immunoreactivity and intracellular staining pattern are associated with keratinocyte differentiation state. Our results are consistent with the established pathogenic model of AAGAB in PPPK1 and with altered epidermal homeostasis in affected skin. This study underscores the value of integrating clinical, histopathological, and molecular data for accurate genotype–phenotype correlation in inherited keratodermas.
- 18 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2674
Open AccessClinical and Molecular Characterization of a Family with Punctate Palmoplantar Keratoderma Type 1 (AAGAB-pEDD) Carrying a Previously Unreported AAGAB Nonsense Variant
Background: Punctate palmoplantar keratoderma type 1 (PPPK1) is a rare inherited disorder characterized by hyperkeratotic papules affecting the palms and soles. AAGAB-related PPPK1 has recently been designated AAGAB-pEDD within a proposed gene-based classification of palmoplantar epidermal differentiation disorders. Here, we describe a multi-generational family in which we identified a previously unreported heterozygous nonsense variant in AAGAB, NM_024666.5:c.739C>T (p.Gln247Ter). The variant was identified in the proband and her affected father, as well as in her 15-year-old daughter, who is currently unaffected. This familial distribution is compatible with the autosomal dominant inheritance and age-dependent penetrance described for PPPK1. Methods: Clinical and histopathological evaluations were performed in the affected family members, followed by molecular genetic analysis to identify the underlying AAGAB variant. Variant interpretation was conducted according to established criteria. Immunofluorescence analysis of lesional skin was performed to investigate AAGAB expression and distribution. In addition, calcium-induced differentiation of Ker-CT keratinocytes was used to assess changes in AAGAB expression alongside the differentiation markers K14 and K10. Results: The previously unreported heterozygous nonsense variant in AAGAB, p.Gln247Ter variant, introduces a premature termination codon, and it is predicted to result in AAGAB loss of function through nonsense-mediated mRNA decay and/or production of a truncated protein lacking the C-terminal region if the mutant transcript were to escape NMD, contributing to AAGAB dimerization and interactions with the AP1 and AP2 adaptor complexes. Immunofluorescence analysis of lesional skin showed an altered pattern of AAGAB immunoreactivity in suprabasal keratinocytes. During calcium-induced differentiation of Ker-CT keratinocytes, representative immunofluorescence images showed an apparent reduction in AAGAB staining, accompanied by decreased K14 and increased K10 expression. Conclusions: These findings expand the mutational spectrum of AAGAB-related PPPK1 and provide additional evidence that AAGAB immunoreactivity and intracellular staining pattern are associated with keratinocyte differentiation state. Our results are consistent with the established pathogenic model of AAGAB in PPPK1 and with altered epidermal homeostasis in affected skin. This study underscores the value of integrating clinical, histopathological, and molecular data for accurate genotype–phenotype correlation in inherited keratodermas.
- Open Access
- 5 October 2026
- Published by Springer Nature in Cell Death Discovery
Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.
- 5 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessCholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.
- Open Access
- 12 January 2026
- Published by Springer Nature in Biology Direct
- Vol. 21 (1)
Solute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma
Solute carrier family (SLC) amino acid transporters play key role in maintaining a continuous supply of nutrients to cancer cells. Non melanoma skin tumour
- 12 January 2026
- Published by Springer Nature in Biology Direct
- Vol. 21 (1)
Open AccessSolute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma
Solute carrier family (SLC) amino acid transporters play key role in maintaining a continuous supply of nutrients to cancer cells. Non melanoma skin tumour
- Top Cited PapersOpen Access
- 27 December 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 16 (1)
PGC-1α: key regulator of mitochondrial biogenesis and cellular differentiation in metabolic and regenerative tissues
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a crucial coactivator that regulates mitochondrial biogenesis and fu
- 27 December 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 16 (1)
Top Cited PapersOpen AccessPGC-1α: key regulator of mitochondrial biogenesis and cellular differentiation in metabolic and regenerative tissues
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a crucial coactivator that regulates mitochondrial biogenesis and fu
- Open Access
- 17 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (29)
Deletion of p63 exon 13 in mice reveals C-terminal isoform–specific functions in epithelial development
The transcription factor p63 is an essential regulator of epithelial development. Yet, the complexity at the 3′UTR, which gives rise to the three distinct C-terminal protein isoforms (α, β, and γ), remains unresolved and opens an investigation on the in vivo role of the C-terminus. This region, codified by exon 13, harbors genetic mutations leading to AEC syndrome. Here, we generated a mouse with a deletion of p63 exon 13 in keratin-14-expressing tissues and employed transcriptome, genome-wide occupancy, and interactome studies to characterize the role of the p63 C-terminus in vivo. In this model mouse, the p63 protein is expressed at the correct level in time and space but predominantly as the β isoform instead of the α isoform, thereby providing insights into the function of the C-terminus. We show that p63β interacts more readily with the core promoter transcription machinery and p63α-depleted isoforms bind more frequently the promoter region of target genes, resulting in inappropriate overexpression of extracellular matrix organization genes in the skin. This leads to the aberrant adhesion of epidermal keratinocytes to the basal lamina and triggers systemic inflammation, growth abnormalities, and premature death. We found a significant role of the full-length ΔNp63a isoform which cannot be substituted by the other isoforms (β or γ). Our studies highlight a crucial role for p63α in correctly orchestrating the gene expression program to ensure proper formation of epithelia.
- 17 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (29)
Open AccessDeletion of p63 exon 13 in mice reveals C-terminal isoform–specific functions in epithelial development
The transcription factor p63 is an essential regulator of epithelial development. Yet, the complexity at the 3′UTR, which gives rise to the three distinct C-terminal protein isoforms (α, β, and γ), remains unresolved and opens an investigation on the in vivo role of the C-terminus. This region, codified by exon 13, harbors genetic mutations leading to AEC syndrome. Here, we generated a mouse with a deletion of p63 exon 13 in keratin-14-expressing tissues and employed transcriptome, genome-wide occupancy, and interactome studies to characterize the role of the p63 C-terminus in vivo. In this model mouse, the p63 protein is expressed at the correct level in time and space but predominantly as the β isoform instead of the α isoform, thereby providing insights into the function of the C-terminus. We show that p63β interacts more readily with the core promoter transcription machinery and p63α-depleted isoforms bind more frequently the promoter region of target genes, resulting in inappropriate overexpression of extracellular matrix organization genes in the skin. This leads to the aberrant adhesion of epidermal keratinocytes to the basal lamina and triggers systemic inflammation, growth abnormalities, and premature death. We found a significant role of the full-length ΔNp63a isoform which cannot be substituted by the other isoforms (β or γ). Our studies highlight a crucial role for p63α in correctly orchestrating the gene expression program to ensure proper formation of epithelia.
- Open Access
- 9 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-10
Mesenchymal stromal cells highly expressing Sca-1 promote breast cancer lung metastasis through recruiting myeloid cells
Mesenchymal stem/stromal cells (MSCs) are integral components of the tumor microenvironment and critical for the colonization of disseminated cancer cells; specifically, stem cell antigen (Sca-1) is recognized as a surface marker of MSCs. In this study, we found that MSCs highly expressing Sca-1 are positively associated with lung metastasis. MSCs derived from the lungs of mice bearing metastasized breast tumors (LMSCs) exhibited higher level of Sca-1 compared to those with adenoma. When co-injected with 4T1 cells intravenously, Sca-1high LMSCs resulted in more tumor nodules in lung tissue than Sca-1low LMSCs. Furthermore, Sca-1high LMSCs expressed higher levels of CCL2, CCL7, and CXCL1 than Sca-1low LMSCs. Sca-1high LMSCs can directly recruit 4T1 cells through producing CXCL1. Additionally, Sca-1high LMSCs are highly potent in recruiting immune cells of the myeloid lineage (neutrophils and macrophages) to the lungs. Inhibition of macrophage chemotaxis by Bindarit, an inhibitor of CCL2/7/8 transcription, decreased the lung tumor burden induced by Sca-1high MSCs. Using Ccr5 −/− mice, it was further confirmed that Sca-1high LMSCs promote tumorigenesis by recruiting macrophages, further supporting that the increased recruitment of macrophages mediates the pro-metastasis effect of Sca-1high LMSCs. Collectively, this study demonstrated that Sca-1high LMSCs and their effectors could be targeted to inhibit breast cancer metastasis to the lung.
- 9 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-10
Open AccessMesenchymal stromal cells highly expressing Sca-1 promote breast cancer lung metastasis through recruiting myeloid cells
Mesenchymal stem/stromal cells (MSCs) are integral components of the tumor microenvironment and critical for the colonization of disseminated cancer cells; specifically, stem cell antigen (Sca-1) is recognized as a surface marker of MSCs. In this study, we found that MSCs highly expressing Sca-1 are positively associated with lung metastasis. MSCs derived from the lungs of mice bearing metastasized breast tumors (LMSCs) exhibited higher level of Sca-1 compared to those with adenoma. When co-injected with 4T1 cells intravenously, Sca-1high LMSCs resulted in more tumor nodules in lung tissue than Sca-1low LMSCs. Furthermore, Sca-1high LMSCs expressed higher levels of CCL2, CCL7, and CXCL1 than Sca-1low LMSCs. Sca-1high LMSCs can directly recruit 4T1 cells through producing CXCL1. Additionally, Sca-1high LMSCs are highly potent in recruiting immune cells of the myeloid lineage (neutrophils and macrophages) to the lungs. Inhibition of macrophage chemotaxis by Bindarit, an inhibitor of CCL2/7/8 transcription, decreased the lung tumor burden induced by Sca-1high MSCs. Using Ccr5 −/− mice, it was further confirmed that Sca-1high LMSCs promote tumorigenesis by recruiting macrophages, further supporting that the increased recruitment of macrophages mediates the pro-metastasis effect of Sca-1high LMSCs. Collectively, this study demonstrated that Sca-1high LMSCs and their effectors could be targeted to inhibit breast cancer metastasis to the lung.
- Open Access
- 8 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance
To uncover substrates mediating the oncogenic activity of WWP1 in acute myeloid leukemia (AML), we performed a proteomic analysis that identified the histone demethylase KDM5B /JARID1B as a candidate target. Of note, JARID1B is indispensable for efficient recruitment of several DNA damage repair factors and for damage resolution, thus negatively influencing the sensitivity of cancer cells to chemo- and radiation therapies. Validation of JARID1B as a substrate of WWP1 revealed a positive regulation of JARID1B half-life by WWP1 through the establishment of K63-linked polyubiquitin chains. As a result, downregulation of JARID1B rising from WWP1 inactivation was associated with higher H3K4me3 enrichment at JARID1B target genes in WWP1-depleted relatively to control AML cells. Integration of RNA-seq and H3K4me3 ChIP-seq data uncovered a highly significant overlap between upregulated gene expression and enriched H3K4me3 peaks after shWWP1 inactivation. We confirmed transcriptional activation of JARID1B targets in WWP1-depleted cells, supporting a role for WWP1 in regulating JARID1B activity. Coherently, upon WWP1 inactivation, we observed a defective recruitment of repair proteins after DNA damage, with subsequent reduced DNA damage repair efficiency and enhanced sensitization of AML cells to the cytotoxic activity of chemotherapeutic drugs. All together, these data identify JARID1B as a bona fide target of WWP1 and imply that WWP1-mediated regulation of JARID1B impacts its ability to modify chromatin and to recruit DNA damage repair factors, thus ultimately affecting chemosensitivity of AML cells.
- 8 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
Open AccessThe WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance
To uncover substrates mediating the oncogenic activity of WWP1 in acute myeloid leukemia (AML), we performed a proteomic analysis that identified the histone demethylase KDM5B /JARID1B as a candidate target. Of note, JARID1B is indispensable for efficient recruitment of several DNA damage repair factors and for damage resolution, thus negatively influencing the sensitivity of cancer cells to chemo- and radiation therapies. Validation of JARID1B as a substrate of WWP1 revealed a positive regulation of JARID1B half-life by WWP1 through the establishment of K63-linked polyubiquitin chains. As a result, downregulation of JARID1B rising from WWP1 inactivation was associated with higher H3K4me3 enrichment at JARID1B target genes in WWP1-depleted relatively to control AML cells. Integration of RNA-seq and H3K4me3 ChIP-seq data uncovered a highly significant overlap between upregulated gene expression and enriched H3K4me3 peaks after shWWP1 inactivation. We confirmed transcriptional activation of JARID1B targets in WWP1-depleted cells, supporting a role for WWP1 in regulating JARID1B activity. Coherently, upon WWP1 inactivation, we observed a defective recruitment of repair proteins after DNA damage, with subsequent reduced DNA damage repair efficiency and enhanced sensitization of AML cells to the cytotoxic activity of chemotherapeutic drugs. All together, these data identify JARID1B as a bona fide target of WWP1 and imply that WWP1-mediated regulation of JARID1B impacts its ability to modify chromatin and to recruit DNA damage repair factors, thus ultimately affecting chemosensitivity of AML cells.
- Open Access
- 7 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a common and aggressive malignancy. While significant advances have been made in the management of low-grade cancer, treatment of advanced HNSCC remains challenging. Here, we used a proteomic approach to find binding partners of the oncogene p63, the most frequently amplified transcription factor in HNSCC. We identified a zinc finger protein, ZNF148, which is coexpressed and physically binds p63 in carcinoma cells. Genome occupancy analyses identified a functional transcribed enhancer-derived RNA (eRNA) upstream of the CCND1 gene occupied by both factors. Mechanistically, p63 and ZNF148 control transcription of this eRNA, leading to overexpression of cyclin D1 to reinforce tumor cell proliferation. Importantly, this axis is specific for cancer cells and remains inactive in normal epithelial cells. The expression levels of these factors and the eRNA are positively correlated in cancer and associated with advanced stage and metastasis. Collectively, our data reveal a molecular pathway controlling HNSCC progression and identify potential selective targets for cancer treatment.
- 7 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
Open Accessp63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a common and aggressive malignancy. While significant advances have been made in the management of low-grade cancer, treatment of advanced HNSCC remains challenging. Here, we used a proteomic approach to find binding partners of the oncogene p63, the most frequently amplified transcription factor in HNSCC. We identified a zinc finger protein, ZNF148, which is coexpressed and physically binds p63 in carcinoma cells. Genome occupancy analyses identified a functional transcribed enhancer-derived RNA (eRNA) upstream of the CCND1 gene occupied by both factors. Mechanistically, p63 and ZNF148 control transcription of this eRNA, leading to overexpression of cyclin D1 to reinforce tumor cell proliferation. Importantly, this axis is specific for cancer cells and remains inactive in normal epithelial cells. The expression levels of these factors and the eRNA are positively correlated in cancer and associated with advanced stage and metastasis. Collectively, our data reveal a molecular pathway controlling HNSCC progression and identify potential selective targets for cancer treatment.
- Open Access
- 3 June 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-9
LEADR, a p63 target, dampens interferon signalling in bladder cancer
Bladder cancer affects over half a million people worldwide each year. Recent advances in early detection allowed a successful management of non-aggressive cancers, yet the recurrence rate remains high. Aggressive muscle-invasive bladder tumours are life-threatening and challenging to cure. Therefore, understanding of key molecular pathways involved in cancer progression is critical for developing of new personalised targeted therapies. Recently, non-coding RNAs (ncRNAs) have emerged as key regulators orchestrating complex biological processes in cancer, yet their function is not fully understood. Here, we compare non-muscle invasive and muscle invasive cell lines and identify a ncRNA gene MIR205HG and its transcript LEADR among the top ncRNAs downregulated in muscle invasive urothelial tumours. We show that LEADR expression is epigenetically regulated by master transcription factor p63. LEADR is localised in the nuclei of non-muscle invasive bladder cancer cells where it dampens hyperactivation of interferon stimulated genes possibly increasing sensitivity of bladder cancer cells to interferon signalling. These findings uncover an anti-tumoral role of non-coding RNA LEADR in mediating immune response in bladder cancer.
- 3 June 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-9
Open AccessLEADR, a p63 target, dampens interferon signalling in bladder cancer
Bladder cancer affects over half a million people worldwide each year. Recent advances in early detection allowed a successful management of non-aggressive cancers, yet the recurrence rate remains high. Aggressive muscle-invasive bladder tumours are life-threatening and challenging to cure. Therefore, understanding of key molecular pathways involved in cancer progression is critical for developing of new personalised targeted therapies. Recently, non-coding RNAs (ncRNAs) have emerged as key regulators orchestrating complex biological processes in cancer, yet their function is not fully understood. Here, we compare non-muscle invasive and muscle invasive cell lines and identify a ncRNA gene MIR205HG and its transcript LEADR among the top ncRNAs downregulated in muscle invasive urothelial tumours. We show that LEADR expression is epigenetically regulated by master transcription factor p63. LEADR is localised in the nuclei of non-muscle invasive bladder cancer cells where it dampens hyperactivation of interferon stimulated genes possibly increasing sensitivity of bladder cancer cells to interferon signalling. These findings uncover an anti-tumoral role of non-coding RNA LEADR in mediating immune response in bladder cancer.
- Open Access
- 14 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 645
Implications of Mineralization Biomarkers in Breast Cancer Outcomes Beyond Calcifications
The aim of this work was to explore the biomarkers associated with epithelial to mesenchymal transition (EMT) and mineralization processes as new prognostic factors across different breast cancer phenotypes. To this end, 133 breast biopsies, including benign and malignant lesions, with or without microcalcifications, were retrospectively collected. Immunohistochemical analysis was performed to evaluate the expression of vimentin, BMP-2, BMP-4, RANKL, Runx2, OPN, PTX3, and SDF-1, while Kaplan—Meier plots were used to assess their prognostic impact on overall survival in a dataset of 2976 breast cancer patients. The expression of vimentin, BMP-2, BMP-4, and SDF-1 was significantly higher in malignant lesions compared to benign ones, regardless of the presence of microcalcifications. Notably, these markers showed no correlation with traditional prognostic factors, such as tumor grade or hormone receptor status. The bioinformatics analysis provided valuable insights into the possible prognostic and therapeutic significance of BMP-2, BMP-4, SDF-1, and vimentin in breast cancer. In fact, all these biomarkers impact on the overall survival in specific molecular breast cancer types. In addition, high expression of SDF-1 and vimentin is able to predict the response to chemotherapy. The findings here reported suggest that vimentin, BMP-2, BMP-4, and SDF-1 could be independent prognostic biomarkers in breast cancer, providing insights beyond traditional clinical factors.
- 14 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 645
Open AccessImplications of Mineralization Biomarkers in Breast Cancer Outcomes Beyond Calcifications
The aim of this work was to explore the biomarkers associated with epithelial to mesenchymal transition (EMT) and mineralization processes as new prognostic factors across different breast cancer phenotypes. To this end, 133 breast biopsies, including benign and malignant lesions, with or without microcalcifications, were retrospectively collected. Immunohistochemical analysis was performed to evaluate the expression of vimentin, BMP-2, BMP-4, RANKL, Runx2, OPN, PTX3, and SDF-1, while Kaplan—Meier plots were used to assess their prognostic impact on overall survival in a dataset of 2976 breast cancer patients. The expression of vimentin, BMP-2, BMP-4, and SDF-1 was significantly higher in malignant lesions compared to benign ones, regardless of the presence of microcalcifications. Notably, these markers showed no correlation with traditional prognostic factors, such as tumor grade or hormone receptor status. The bioinformatics analysis provided valuable insights into the possible prognostic and therapeutic significance of BMP-2, BMP-4, SDF-1, and vimentin in breast cancer. In fact, all these biomarkers impact on the overall survival in specific molecular breast cancer types. In addition, high expression of SDF-1 and vimentin is able to predict the response to chemotherapy. The findings here reported suggest that vimentin, BMP-2, BMP-4, and SDF-1 could be independent prognostic biomarkers in breast cancer, providing insights beyond traditional clinical factors.